L-3,4-Dihydroxyphenylalanine Methyl ester hydrochloride
L-3,4-Dihydroxyphenylalanine Methyl ester hydrochloride structure
|
Common Name | L-3,4-Dihydroxyphenylalanine Methyl ester hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1421-65-4 | Molecular Weight | 247.676 | |
| Density | 1.322g/cm3 | Boiling Point | 384.4ºC at 760mmHg | |
| Molecular Formula | C10H14ClNO4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 186.3ºC | |
|
Striatal astrocytes act as a reservoir for L-DOPA.
PLoS ONE 9(9) , e106362, (2014) L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and metabolis... |
|
|
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
J. Neurosci. Res. 92(12) , 1733-45, (2014) L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is the most common complication of standard L-DOPA therapy for Parkinson's disease experienced by most parkinsonian patients. LID is associated with disruption of dopaminergic homeostasis in basal... |
|
|
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.
Synapse 68(8) , 332-43, (2014) l-3,4-Dihydroxyphenylalanine (L-DOPA) is the most widely used drug for the treatment of Parkinson's disease. Unfortunately, chronic administration of this dopamine precursor causes L-DOPA-induced dyskinesia (LID), which is a debilitating complication whose pa... |
|
|
Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.
Eur. J. Drug Metab. Pharmacokinet. 39(4) , 237-42, (2014) The objective of this study was to investigate the pharmacokinetic characteristics of levodopa (L-dopa) from nasal powder formulations using highly water-soluble levodopa methyl ester hydrochloride (LDME). In vivo pharmacokinetic studies were carried out with... |
|
|
Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat.
J. Neurochem. 68 , 233-239, (1997) The effectiveness of intranasal drug administration to stimulate central neuronal systems is well known from drug addiction and has also been considered as an alternative pharmacokinetic approach to treat brain disorders such as Parkinson's disease. In the pr... |
|
|
The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice.
Pharmacol. Biochem. Behav. 33 , 139-146, (1989) Mice were treated for 28 days with drinking water containing L-DOPA methyl ester hydrochloride (DME) plus carbidopa, carbidopa alone, or with the vehicle. All mice were then given the vehicle for 1 day and behavioural and biochemical assessments made on the 2... |
|
|
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Eur. J. Pharmacol. 599(1-3) , 81-5, (2008) The effects of biperiden (0, 100, and 320 microg/kg), a selective muscarinic M(1)/M(4) receptor cholinergic antagonist, were studied alone and in combination with those of L-DOPA methyl ester (16.7 mg/kg), a selective dopamine D(1) receptor agonist SKF-82958 ... |
|
|
Determination of levodopa methyl ester and its metabolites in rat serum by CZE with amperometric detection.
Anal. Bioanal. Chem 382(1) , 198-203, (2005) A reliable and reproducible method, capillary zone electrophoresis with amperometric detection (CZE-AD), has been developed for separation and quantification of levodopa methyl ester (LDME) and its biotransformation products levodopa (L-DOPA) and dopamine (DA... |
|
|
Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets.
Eur. J. Pharm. Biopharm. 53(2) , 227-32, (2002) A versatile oral controlled release system for the simultaneous delivery of levodopa methyl ester and carbidopa, consisting of a three-layer matrix tablet, has been studied and developed. Each individual layer of the matrix exhibited a different release mecha... |
|
|
Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys.
Clin. Neuropharmacol. 22(5) , 281-7, (1999) We assessed the antiparkinsonian response in MPTP-treated monkeys after acute or repeated treatment with oral L-Dopa, subcutaneous administration of L-Dopa methyl ester (LDME) or apomorphine, alone and in combination with D1 antagonists SCH 23390 (SCH) or NNC... |